Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids
Mallick P, Song G, Efremenko A, Pendse S, Creek M, Osimitz T, Hines R, Hinderliter P, Clewell H, Lake B, Yoon M, Moreau M. Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids. Toxicological Sciences 2020, 176: 460-469. PMID: 32421774, PMCID: PMC7416317, DOI: 10.1093/toxsci/kfaa070.Peer-Reviewed Original ResearchConceptsAge-related pharmacokinetic differencesPharmacokinetic differencesPBPK modelTarget tissue exposureAge-related sensitivityHuman PBPK modelAge-dependent changesAge-related differencesRat modelTissue exposureVivo rat dataPharmacokinetic modellingPharmacokinetic modelingInternal exposureRat dataRisk assessmentVivo extrapolationRisk assessment purposesExposureAdultsExternal exposureSensitive populationsChildrenMetabolic capacityAssessmentAnalyzing Metabolomics Data for Environmental Health and Exposome Research
Cai Y, Rosen Vollmar AK, Johnson CH. Analyzing Metabolomics Data for Environmental Health and Exposome Research. Methods In Molecular Biology 2020, 2104: 447-467. PMID: 31953830, DOI: 10.1007/978-1-0716-0239-3_22.Peer-Reviewed Original ResearchConceptsLiquid chromatography-mass spectrometryChromatography-mass spectrometryBiological samplesExposure chemicalsExternal exposureSimultaneous analysisExposome researchHealth outcomesDisease preventionUnique advantagesBiological responsesUntargeted metabolomicsExposure risk assessmentHost susceptibilityMetabolomics technologyExposomeMetabolomic analysisRecent advancesSpectrometryExposureUntargeted metabolomics dataMetabolomicsHuman healthMetabolomics dataCumulative measure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply